BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 3530592)

  • 1. Effects of glipizide on various consecutive insulin secretory stimulations in patients with type 2 diabetes.
    Ahrén B; Lundquist I; Scherstén B
    Diabetes Res; 1986 Jul; 3(6):293-300. PubMed ID: 3530592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose tolerance and insulin and C-peptide responses after various insulin secretory stimuli in hyper- and hypothyroid subjects before and after treatment.
    Ahrén B; Lundquist I; Hedner P; Valdemarsson S; Scherstén B
    Diabetes Res; 1985 Mar; 2(2):95-103. PubMed ID: 2412749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of sulfonylurea on glucose, insulin and C-peptide responses to a meal stimulus in a patient with type 2 diabetes and liver disease.
    Ahrén B; Scherstén B
    Acta Med Scand; 1984; 215(5):487-91. PubMed ID: 6430037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sulphonylurea on glucose-stimulated insulin secretion in healthy and non-insulin dependent diabetic subjects: a dose-response study.
    Groop LC; Ratheiser K; Luzi L; Melander A; Simonson DC; Petrides A; Bonadonna RC; Widén E; DeFronzo RA
    Acta Diabetol; 1991; 28(2):162-8. PubMed ID: 1777653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glipizide increases plasma insulin but not C-peptide level after a standardized breakfast in type 2 diabetic patients.
    Scheen AJ; Lefebvre PJ; Luyckx AS
    Eur J Clin Pharmacol; 1984; 26(4):471-4. PubMed ID: 6376145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extrapancreatic effects of a sulphonylurea. Decrease in xylose absorption by glipizide in type II diabetics.
    Kollind M; Adamson U; Lins PE; Ohlsén P
    Acta Med Scand; 1984; 215(5):443-5. PubMed ID: 6377829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of sulfonylureas on the secretion, disposal and effect of insulin.
    Almér LO; Johansson E; Melander A; Wåhlin-Boll E
    Eur J Clin Pharmacol; 1982; 22(1):27-32. PubMed ID: 7047169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The plasma C-peptide and insulin responses to stimulation with intravenous glucagon and a mixed meal in well-controlled type 2 (non-insulin-dependent) diabetes mellitus: dependency on acutely established hyperglycaemia.
    Gjessing HJ; Reinholdt B; Pedersen O
    Diabetologia; 1989 Dec; 32(12):858-63. PubMed ID: 2693165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sulfonylurea on the secretion and disposition of insulin and C-peptide.
    Almér LO; Johansson E; Melander A; Wåhlin-Boll E
    Acta Med Scand Suppl; 1981; 656():11-8. PubMed ID: 7046346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The acute effect of preprandial exogenous and endogenous sulphonylurea-stimulated insulin secretion on postprandial glucose excursions in patients with type 2 diabetes.
    Groop PH; Melander A; Groop LC
    Diabet Med; 1993; 10(7):633-7. PubMed ID: 8403824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of glipizide on insulin secretion and insulin metabolism in obese type II diabetic patients.
    Bonora E; Pisani F; Micciolo R; Corgnati A; Muggeo M
    Diabetes Care; 1987; 10(6):687-91. PubMed ID: 3322723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of glipizide on insulin secretion and blood glucose control in patients with non-insulin-dependent diabetes mellitus.
    Bitzén PO; Melander A; Scherstén B; Svensson M; Wåhlin-Boll E
    Eur J Clin Pharmacol; 1992; 42(1):77-83. PubMed ID: 1541320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects.
    Groop L; Luzi L; Melander A; Groop PH; Ratheiser K; Simonson DC; DeFronzo RA
    Diabetes; 1987 Nov; 36(11):1320-8. PubMed ID: 3117609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin secretory capacity and the regulation of glucagon secretion in diabetic and non-diabetic alcoholic cirrhotic patients.
    Kruszynska YT; Goulas S; Wollen N; McIntyre N
    J Hepatol; 1998 Feb; 28(2):280-91. PubMed ID: 9514541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoreactive insulin and C-peptide responses to various insulin secretory stimuli in subjects with type 2 diabetes and in control subjects during continuous glucose monitoring.
    Ahrén B; Scherstén B; Agardh CD; Lundquist I
    Acta Med Scand; 1981; 210(5):337-48. PubMed ID: 7039239
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of glipizide gastrointestinal therapeutic system on islet cell hormonal responses to a test meal in NIDDM.
    Mooradian AD; Albert SG; Bernbaum M; Plummer S
    Diabetes Care; 1996 Aug; 19(8):883-4. PubMed ID: 8842609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered C-peptide/insulin molar ratios and glucose turnover rates after stimulation in nondiabetic offsprings of type II diabetic patients.
    Osei K; Holland GC
    Metabolism; 1987 Feb; 36(2):122-7. PubMed ID: 3543613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of ethanol and glipizide in humans.
    Hartling SG; Faber OK; Wegmann ML; Wåhlin-Boll E; Melander A
    Diabetes Care; 1987; 10(6):683-6. PubMed ID: 3428047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics.
    Groop L; Wåhlin-Boll E; Groop PH; Tötterman KJ; Melander A; Tolppanen EM; Fyhrqvist F
    Eur J Clin Pharmacol; 1985; 28(6):697-704. PubMed ID: 3933984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.